Developing a new drug is expensive and takes a number of years, the complexity of the disease and the size of clinical trials will have an impact on both.
Estimates across different disease areas varies, central nervous system (CNS) drugs which include a variety of neurological diseases including Alzheimer’s disease, are widely reported to be one of the most expensive areas. However, the number of Alzheimer’s disease clinical trials has almost doubled in three years.
Page last reviewed: 18/06/2018
Source: Search conducted on clinicaltrials.gov on 15 July 2016, showed 194 open trials (Search criteria ¬ Interventional (drug) studies phase 1-3, with ongoing (not unknown) status). Comparison to search on 8 July 2013, which showed 99 trials, cited in Alzheimer’s Society Dementia 2014 report
Source: Medicines and vaccines –have helped deliver improved patient health and overall survival; Association of British Pharmaceuticals (2012)
Source: Time to flourish – Inside innovation: the medicine development process; The Association of the British Pharmaceutical Industry (2012)
Source: Time to flourish – Inside innovation: the medicine development process; The Association of British Pharmaceuticals (2012)
Source: EU Clinical Trial registry (18/06/2018) Search terms “dementia” and “cancer”
Source: Clinical Trials – A report from the Ministerial Industry Strategy Group Clinical Research Group (2018)